Topiramate, Zonisamide and Small For Gestational Age: Maternal Factors, Timing of Exposure and Baby Fat

**Association Between Topiramate and Zonisamide Use During Pregnancy and Low Birth Weight.**

The recent article from the North American Antiepileptic Drug Pregnancy Registry (NAAEDPR) presents data showing that babies exposed in utero to topiramate (TPM) and zonisamide (ZNS) have a significantly lower birth weight and shorter length than babies exposed to lamotrigine (LTG) or a control group. This difference, of a mean of 200 grams in weight and 1 cm in length, when controlled for gestational age, contributed to a higher than expected proportion of babies who were small for gestational age (SGA) occurring in the TPM and ZNS groups.

**Commentary**
Small for gestational age (SGA) is commonly defined as weight below the 10th percentile for gestational age (1). The concern regarding SGA is its implications for development; it is associated with an increased risk for neonatal distress, permanent deficits in growth and neurocognitive development, and mortality. However, SGA babies are a heterogeneous group, and approximately 50% are constitutionally small, due to maternal ethnicity, body habitus, and body mass index (BMI) and these infants will develop normally (2). In 2005, 10% of births to Hispanic, American Indian/Alaska Native, and non-Hispanic white women in the United States met the criteria for SGA, and the occurrence in non-Hispanic Black births was 17% (1).

Topiramate is associated with an increased risk of major congenital malformations (MCMs), with 1.4 % of births showing facial clefts, recently described by this group (3, 4) and others (5). These rare cases were excluded from the analysis herein. Within the North American Antiepileptic Drug Pregnancy Registry (NAAEDPR), a structurally related drug, zonisamide has been associated with a low risk of MCMs, with none occurring in 90 monotherapy exposures, therefore the upper limit of the 95% confidence interval (CI) is 3.3% (3).

The authors adjusted for many factors that could contribute to small for gestational age, including smoking, maternal illness, and socioeconomic indicators. The overwhelming majority of mothers were Caucasian (> 85%) which minimizes the ethnic variability that could result in some SGA babies. This was also very highly educated cohort. Having at least 2 years of college education was reported in 45% of the topiramate-treated mothers, and this was the least educated group.

The investigators also evaluated factors that would not be predicted to associate with SGA, but need to be looked at just the same, such as the indication for use including migraine and epilepsy. They found no association by indication. Overall, this appears to be a group with low risk for ethnic or socioeconomic influences on the occurrence of SGA. Therefore these rates may be underestimates for other populations.

An epilepsy-related factor that associates with SGA is the occurrence of seizures during pregnancy (6). This was evaluated and showed no association.

Another epilepsy-related factor associated with SGA is AED polytherapy (7). The authors evaluated a group exposed to lamotrigine plus other AEDs and found an SGA proportion of 10%, lower than that with topiramate or zonisamide polytherapy. Polytherapy exposures, although incompletely described in this report and not discussed as independent groups, showed a trend toward an adverse effect. From the spectrum of AED associations with SGA, TPM as monotherapy or polytherapy carried the most risk.

The question as to the underlying mechanism of topiramate-associated SGA is paramount. Weight loss surely does occur with these AEDs, and TPM is now marketed as part of a combination pharmaceutical agent having an indication for the treatment of severe obesity (8). An obvious limitation of this study is that maternal weight and maternal weight change during pregnancy were not adjusted for in this analysis, since they are associated with either SGA or LGA (large for gestational age) (9). It was stated, however, that the data was not available for such.

Topiramate’s mechanism of action in producing weight loss may be primarily through the hypothalamus, affecting both the sense of satiety mediated in the ventromedial hypothalamus and hunger recognition mediated in the lateral hypothalamus. Decreased gastric motility has also been proposed as a contributing mechanism, controlled in the dorsomedial
hypothalamic nucleus. One recent report (10) supports this hypothesis; in a study of 40 migraine patients treated with topiramate 100 mg/day for three months, a significant reduction in body fat occurred, without a change in the resting metabolic rate (RMR), pointing toward a hypothalamic mechanism.

There was no dose effect found, but there was a profound timing effect. The proportion of SGA in offspring whose mothers stopped topiramate monotherapy before the third trimester was quite low at 7.3%, while for those who continued it throughout the third trimester, the rate was highest at 19.6%. This difference was not significant, likely due to small numbers (not given), but the trend is interesting, as is the trend polytherapy on increasing the rates of SGA especially with topiramate use.

The third trimester is the period of gestation when most fetal body fat is deposited. At 20-weeks gestation, fat comprises 0.5% of the fetal body, after which the amount increases, reaching 7.8% at the 34-weeks gestation, and 16% before birth. Nearly 500 g of fetal body fat are acquired in the last trimester of pregnancy and during the last month of intrauterine life the fetus gains as much as 14 g of fat per day (11). Does topiramate minimize fetal body fat deposition, as suggested by timing of an adverse effect in correlation with fetal growth patterns?

This information, while incomplete and difficult to explain since fetuses don’t eat and we do not have information on maternal weight gain, deserves consideration when counseling women with epilepsy and migraine who take these medications. These mothers may need to consciously override their hypothalamically-mediated behavior and eat more!

by Cynthia L. Harden, M.D.

References
2. Royal College of Obstetricians and Gynaecologists. The Investigation and Management of the Small-For-Gestational-Age Fetus Guideline. No. 31. 2002
Disclosure of Potential Conflicts of Interest

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. The work under consideration for publication.
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Other relationships
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
American Epilepsy Society
Epilepsy Currents Journal
Disclosure of Potential Conflicts of Interest

Section #1 Identifying Information

1. Today’s Date: June 19, 2014

2. First Name  Cynthia   Last Name Harden   Degree MD

3. Are you the Main Assigned Author?  ☑ Yes   ☐ No
   
   If no, enter your name as co-author:

4. Manuscript/Article Title: Topiramate, zonisamide and small for gestational age: Maternal factors, timing of exposure and baby fat

5. Journal Issue you are submitting for:  14.4

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grant</td>
<td>☑</td>
<td></td>
<td>$0.00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consulting fee or honorarium</td>
<td>☑</td>
<td>$0.00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Support for travel to meetings for the study or other purposes</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Payment for writing or reviewing the manuscript</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>☑</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
**Section #3 Relevant financial activities outside the submitted work.**
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td></td>
<td>yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td></td>
<td>yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

**Section #4 Other relationships**
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☑ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
*Epilepsy Currents* Editorial Board